Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
Jardiance is the first SGLT2-inhibitor therapy to prove reduction in risk of cardiovascular death in people with type-II diabetes and established cardiovascular disease
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
If approved or authorized, Paxlovid would be the first oral antiviral of its kind, to combat SARS-CoV-2
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Subscribe To Our Newsletter & Stay Updated
